Black Friday Sale! Save huge on InvestingProGet up to 60% off

AstraZeneca pegs back FTSE after takeover snub

Published 19/05/2014, 13:08

By Tricia Wright and Alistair Smout

LONDON (Reuters) - Britain's top shares fell on Monday, pressured by a sharp drop in pharmaceutical firm AstraZeneca after it rejected rival Pfizer's higher takeover bid.

AstraZeneca dived 12.9 percent after turning down Pfizer's 55 pounds/share take-it-or-leave-it offer.

That steep decline accounted for around three quarters of the fall on the FTSE 100 index, down 41.38 points, or 0.6 percent, at 6,814.43 points by 1108 BST.

AstraZeneca had risen over 27 percent in the month since the first Pfizer bid was reported, and traders said that a deal was now unlikely, with Pfizer reluctant to engage in a hostile approach.

"With Pfizer saying they won't go hostile, it looks like it is pretty much dead," Will Hedden, sales trader at IG, said.

"The rhetoric from certain government sections about securing jobs in the UK will have been a hurdle and certainly put off AstraZeneca shareholders."

Recent price moves have left AstraZeneca trading at a forward price/EPS multiple of 19.5, according to StarMine data, compared to 15.5 for GlaxoSmithKline and 14.3 for Sanofi, and over double its 10-year median of 9.3.

The FTSE 100 retraced the previous week's 0.6 percent gain, which saw the index touch 14-year highs. On Thursday it came within 0.8 percent of all-time highs set in December 1999.

"With the FTSE 100 close to all-time-high territory, concerns have once again been raised in relation to valuation, which is creating something of a headwind," said Jeremy Batstone-Carr, analyst at Charles Stanley.

In common with AstraZeneca, the broader market is also trading above long-run average valuations. The FTSE 100 trades at a price to earnings ratio of 13.8, compared to a 10-year average of 11.8, Thomson Reuters Datastream showed.

EasyJet was among the top risers after expectation-beating results from Irish peer Ryanair.

EasyJet had succumbed to profit taking in recent sessions - down 10 percent last week - as investors cashed in profits on a powerful rally seen over the last 12 months. Its shares rose 1.3 percent on Monday.

(Editing by Toby Chopra)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.